**SUPPLEMENTAL TABLES AND FIGURES**

**Supplemental Table 1. Clinical Characteristics of Patients with and without SAECG**

**Supplemental Table 2. Clinical Characteristics of Patients with Positive Ajmaline and Procainamide Challenges**

**SUPPLEMENTAL APPENDIX.**

**Supplemental Table 1. Clinical Characteristics of Patients with and without SAECG**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **SAECG performed** | **SAECG not performed** | **p-value** |
| Patients | 154 | 271 |  |
| Age (years) | 38.5 ± 15.1 | 39.5 ± 14.9 | 0.505 |
| Sex (male) | 79 (51%) | 152 (56%) | 0.363 |
| Ethnicity Caucasian Asian Other | 120 (77%)11 (7%)23 (15%) | 237 (87%)26 (10%)8 (3%) | **0.013**0.475**<0.0001** |
| Baseline ECG Non-Type 1 Brugada STE (standard leads) Non-Type 1 Brugada STE (high leads)  Non-Type 1 Brugada STE (any leads) | 11 (7%)16 (10%)20 (13%) | 9 (3%)21 (8%)22 (8%) | 0.0950.3740.128 |
| Drug Used for SCB Challenge Procainamide Ajmaline | 57 (37%)97 (63%) | 37 (14%)234 (86%) | **<0.0001** |
| Positive SCB Challenge | 21 (14%) | 68 (25%) | **0.006** |

**Supplemental Table 2. Clinical Characteristics of Patients with Positive Ajmaline and Procainamide Challenges**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Positive Ajmaline** | **Positive Procainamide** | **p-value** |
| Patients | 85 | 4 |  |
| Age (years) | 41.6 ± 14.6 | 48.0 ± 17.1 | 0.394 |
| Sex (male) | 44 (52%) | 3 (75%) | 0.619 |
| Ethnicity Caucasian Asian Other | 80 (94%)4 (5%)1 (1%) | 4 (100%)00 | 1.0001.0001.000 |
| Baseline ECG Non-Type 1 Brugada STE (standard leads) Non-Type 1 Brugada STE (high leads)  Non-Type 1 Brugada STE (any leads) | 5 (6%)17 (20%)17 (20%) | 3 (75%)1 (25%)3 (75%) | **0.002**1.000**0.034** |